

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
12 July 2007 (12.07.2007)

PCT

(10) International Publication Number
WO 2007/077949 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) A61P 25/28 (2006.01)
 C07D 471/14 (2006.01) A61P 35/00 (2006.01)
 A61P 37/06 (2006.01) A61P 35/02 (2006.01)
 A61P 11/06 (2006.01) A61K 31/437 (2006.01)
 A61P 17/00 (2006.01) C07D 451/04 (2006.01)

(21) International Application Number:

PCT/JP2006/326327

(22) International Filing Date:

25 December 2006 (25.12.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2005-378858 28 December 2005 (28.12.2005) JP

(71) Applicant (for all designated States except US): **ASTELLAS PHARMA INC.** [JP/JP]; 3-11 Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8411 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **INOUE, Takayuki** [JP/JP]; c/o Astellas Pharma Inc., 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP). **TANAKA, Akira** [JP/JP]; c/o Astellas Pharma Inc., 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP). **NAKAI, Kazuo** [JP/JP]; c/o Astellas Pharma Inc., 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP). **SASAKI, Hiroshi** [JP/JP]; c/o Astellas Pharma Inc., 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP). **TAKAHASHI, Fumie** [JP/JP]; c/o Astellas Pharma Inc., 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP). **SHIRAKAMI, Shohei** [JP/JP]; c/o Astellas Pharma Inc., 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP). **HATANAKA, Keiko** [JP/JP]; c/o Astellas Pharma Inc., 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP). **NAKAJIMA, Yutaka** [JP/JP]; c/o Astellas Pharma Inc., 3-11, Nihonbashi-Honcho 2-chome,

Chuo-ku, Tokyo 103-8411 (JP). **MUKOYOSHI, Koichiro** [JP/JP]; c/o Astellas Pharma Inc., 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP). **HAM-AGUCHI, Hisao** [JP/JP]; c/o Astellas Pharma Inc., 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP). **KUNIKAWA, Shigeki** [JP/JP]; c/o Astellas Pharma Inc., 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP). **HIGASHI, Yasuyuki** [JP/JP]; c/o Astellas Pharma Inc., 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP).

(74) Agents: **MORITA, Hiroshi** et al.; c/o Astellas Pharma Inc., 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HETEROCYCLIC JANUS KINASE 3 INHIBITORS



(57) Abstract: The present invention provides a compound of formula (I) having an excellent JAK3 inhibition activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases inflammatory diseases, and allergic diseases. The compound according to the present invention has an inhibition activity against JAK3 and is thus useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transmission (e.g., rejection during organ/tissue transplantation, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, Alzheimer's disease, and atherosclerotic disease), or diseases caused by abnormal cytokine signal transmission (e.g., cancer and leukemia).